AstraZeneca to buy US firm ZS Pharma for $2.7bn
It will give UK-based AstraZeneca access to a drug that could potentially treat life-threatening condition, hyperkalaemia.
The drug, ZS-9, is currently under regulatory review by the US Food and Drug Administration.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





